Affordable Access

Access to the full text

Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways

Authors
Type
Published Article
Journal
Biotechnology Advances
Publisher
Elsevier
Publication Date
Nov 24, 2015
Volume
33
Issue
6
Identifiers
DOI: 10.1016/j.biotechadv.2015.03.013
Source
LBMCC
License
Green

Abstract

In addition to apoptosis resistance and cell proliferation capacities, the undifferentiated state also characterizes most cancer cells, especially leukemia cells. Cell differentiation is a multifaceted process that depends on complex regulatory networks that involve transcriptional, post-transcriptional and epigenetic regulation of gene expression. The time- and spatially-dependent expression of lineage-specific genes and genes that control cell growth and cell death is implicated in the process of maturation. The induction of cancer cell differentiation is considered an alternative approach to elicit cell death and proliferation arrest. Differentiation therapy has mainly been developed to treat acute myeloid leukemia, notably with all-trans retinoic acid (ATRA). Numerous molecules from diverse natural or synthetic origins are effective alone or in association with ATRA in both in vitro and in vivo experiments. During the last two decades, pharmaceuticals and natural compounds with various chemical structures, including alkaloids, flavonoids and polyphenols, were identified as potential differentiating agents of hematopoietic pathways and osteogenesis.

Report this publication

Statistics

Seen 274 times